



Wednesday 14 March 2012

Australian Securities Exchange Announcement

MILESTONE REACHED - EXPANDED COVERAGE FOR L-DEX TESTING

Brisbane, Australia – ImpediMed Limited (ASX: IPD) reports today expansion of coverage for its L-Dex® U400 device readings to 23.4 million lives within the United States. The additional coverage is achieved through two new plans; 1) a key Health Maintenance Organization (HMO) and 2) another Third Party Administrator (TPA)

Greg Brown, ImpediMed's CEO said, "The 20 million covered lives milestone is a significant achievement for the Company. The Company remains very focused on building coverage for L-Dex readings as part of a total care program for lymphoedema. Management believes the progress with the TPA and the adoption of clinical guidelines by another key HMO will help build momentum with other key insurers."

The HMO has developed new clinical guidelines which provide a perspective on breast cancer survivorship aimed at improving the patient's quality of life, well being and longevity. Breast Cancer-Related Lymphoedema is among the topics addressed in the guidelines. The guidelines will become active in one key centre of the HMO in May 2012, and roll out to other centres over the coming year.

Greg Brown, ImpediMed's CEO said, "The new HMO survivorship clinical guidelines address prospective care for new patients at risk, as well as provide a general guideline for routine surveillance. More importantly the treatment of these patients, both in the prospective guidelines and routine guidelines ensure appropriate care and treatment of all patients. It is gratifying to see lymphoedema total care addressed for all patients and we hope to see this expand to other forms of lymphoedema in the future."

One of the issues addressed in the clinical guidelines, important for the Company shareholders, calls for the use of bioimpedance spectroscopy (BIS), as an aid in the clinical assessment of female patients, in a pre-emptive model of care for newly diagnosed breast cancer patients.

As per the survivorship guidelines, "The purpose of the clinical guidelines for the management of breast cancer survivorship for practitioners is threefold: 1) Provide the necessary tools to identify the special needs of the breast cancer survivor, 2) Assess, appropriately treat and provide surveillance for the known long term complications of cancer therapy as well as recurrence, 3) Educate and provide support to the patient about appropriate lifestyle / behavioural changes which have been demonstrated to improve overall wellness and survival".

Supply agreements in relation to L-Dex U400 devices have not yet been negotiated with this HMO.

The new TPA offers a unique program covering a fully insured product as well as administering self funded plans. The covering TPA has business in Texas, Louisiana, Georgia, Mississippi, Missouri and Indiana.

Greg Brown

**CEO
ENDS**

For further information contact:

**Greg Brown
ImpediMed CEO
T: 61-7-3860-3700
Mobile/Cell: +61408281127**

L-Dex[®] is a trademark of ImpediMed Limited.

The L-Dex scale is a tool to aid in the clinical assessment of unilateral lymphoedema of the arm in women by a medical provider. The L-Dex scale is not intended to diagnose or predict lymphoedema of an extremity.

About ImpediMed

ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed's primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary lymphoedema of the arm in female breast cancer patients.

For more information, visit: www.impedimed.com.au